| |
h-R3 / Theraloc (handing trade mark)
Oncoscience signed a licence agreement in November 2003 from the
Canadian YM Bioscience and the Cubanian company CIM for their
investigational new drug h-r3 a monoclonal antibody.
The rights for this EGFR-antibody included total 46 countries in
Europe and in the neighbourhood.
European Market
|
Cancer
Type |
EGF-R
expression
(+
ve %) |
Target
Population
Expressing
EGF-R |
|
Head
and
Neck
|
100
|
90,000
|
|
Lung
|
70
|
77,000
|
|
Colorectal
|
90
|
114,300
|
|
Breast
|
40
|
34,400
|
|
Prostate
|
65
|
42,250
|
|
Glioma
|
100
|
15,000
|
|
Stomach
|
50
|
34,000
|
|
Bladder
|
60
|
21,000
|
Oncoscience will start trials (in glioma and pancreatic cancer) in
the second quarter 2004, while YM Bioscience and CIM fill up the ongoing
head and neck trials in Canada and Cuba. |
